Evidence-based medicine and the costs of palliative care

Abstract

As new drugs and technologies become available, the equitable use of resources will demand their assessment using some measure of cost-benefit analysis. But, argues Paul W Keeley, current methods are simply not suitable, or fair, for use in the palliative care population.